Glottic laser surgery: outcomes according to 2007 ELS classification

Eur Arch Otorhinolaryngol. 2011 Dec;268(12):1771-8. doi: 10.1007/s00405-011-1695-7. Epub 2011 Jul 19.

Abstract

The aim of the present investigation was to analyze the oncological results of a series of early stage glottic carcinomas treated with CO(2) laser-assisted endoscopic surgery. We focused on prognosis factors with significant impact on local control and disease-free survival (DFS). This retrospective study was conducted on a series of 177 consecutive patients with pT1-T2 glottic carcinomas treated with CO(2) laser-assisted endoscopic surgery in the period 2000-2007. All considered patients had at least a 24-month follow-up period (mean follow-up 49.1 ± 23.0 months). The overall survival and the disease-specific survival rates were respectively 90.8 and 98.8%. The rates of local control with primary laser surgery, ultimate local control with laser alone, and laryngeal preservation were 86.3, 94.3, and 97.7%, respectively. Arytenoids (p = 0.006) and limited subglottic involvements (p = 0.0002) have a significant impact on DFS. Endoscopic laser surgery is the gold standard in the treatment of early glottic carcinoma because of high local control rates with laser alone, day surgery modality, very low morbility, good post-operative voice quality in most of the cases, and low costs.

Publication types

  • Comparative Study

MeSH terms

  • Carcinoma, Squamous Cell / classification
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / surgery*
  • Disease-Free Survival
  • Europe
  • Female
  • Follow-Up Studies
  • Glottis / pathology
  • Glottis / surgery*
  • Head and Neck Neoplasms / classification
  • Head and Neck Neoplasms / pathology
  • Head and Neck Neoplasms / surgery*
  • Humans
  • Italy / epidemiology
  • Laryngeal Neoplasms / classification
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / surgery*
  • Laryngectomy / methods*
  • Laryngoscopy / methods
  • Laser Therapy / methods*
  • Lasers, Gas / therapeutic use*
  • Male
  • Neoplasm Recurrence, Local
  • Neoplasm Staging
  • Retrospective Studies
  • Societies, Medical
  • Squamous Cell Carcinoma of Head and Neck
  • Survival Rate / trends
  • Time Factors
  • Treatment Outcome